AREVIR, Kln, 08.05.2015 RESINA 2001-2014 Dr. Bjrn Jensen Klinik fr - PowerPoint PPT Presentation

AREVIR, Köln, 08.05.2015 RESINA 2001-2014 Dr. Björn Jensen Klinik für Gastroenterologie, Hepatologie und Infektiologie Universitätsklinikum Düsseldorf

The RESINA Study (Genotypic HIV-Resistance in Treatment-Naives)  Ongoing prospective study in Nordrhein-Westfalen  Inclusion: Untreated HIV-infected subjects before ART initiation  Study period: 2001-2014  Aims of study: – Epidemiology of primary resistance in chronically HIV-infected patients – Evaluation of efficacy of HAART guided by resistance testing – Bioinformatic analysis of resistance data – Subgroup analyses  Classification of resistance: Shafer RW et al., Antiviral Therapy 2009  Until end of 2014: 3811 patients (with sequence) in 36 centers  Funding: – Federal Ministry of Health and Social Security (BMG) – Heinz-Ansmann-Foundation for AIDS-Research

RESINA 2001-2014 Nationality w/o SSA (n=3319) Portugal Spain Others (each N < 10) France 0,4% Netherlands Greece Brazil not documented 0,5% 0,4% 5,1% 0,5% 0,7% 0,3% Germany Poland 1,1% Turkey Italy Ukraine not documented 0,9% 0,3% 3,5% Thailand Russian Federation 1,4% Russian Federation Thailand Poland 1,7% Turkey Italy 2,4% Brazil Greece Spain France Portugal Netherlands Ukraine Others (each N < 10) Germany 80,8%

RESINA 2001-2014 Nationality only SSA(n=372) Cameroon other countries 16,1% 19,1% Sierra Leone Cameroon 2,7% Kenya Kenya Ethiopia Togo 15,9% 3,2% Nigeria Cote d'Ivoire 3,8% Ghana Congo, Republic of (Brazzaville) Cote d'Ivoire Ethiopia Congo, Republic of Sierra Leone (Brazzaville) Togo 6,7% other countries 11,6% Ghana 10,2% Nigeria 10,8%

RESINA 2001-2014 Subtypes (n=2797) subtypes male patients G other A1 01_AE 0,9% 2,1% 4,6% 02_AG 3,5% C 4,4% 1,5% B C 02_AG 01_AE A1 G other B 83,1%

RESINA 2001-2014 Subtypes (n=630) subtypes female patients 12,7% 4,9% 30,3% B C 02_AG 16,0% 01_AE A1 G other 9,5% 7,6% 18,9%

Trends of primary HIV drug resistance: RESINA (n=3452) 16,0% 14,0% 12,0% 10,0% any NRTI 8,0% NNRTI PI 6,0% REVERT 4,0% 2,0% 0,0% 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010 2011-2012 2013-2014

Tropism: RESINA 2001-2014 (n=325) 100,0% 90,0% 80,0% 70,0% 60,0% X4 50,0% X4R5 R5 40,0% 30,0% 20,0% 10,0% 0,0% 2001-2004 2005-2007 2008-2010 2011-2014

Trends of HIV drug resistance: AREVIR (w/o RESINA, after ART) 100 90 80 70 60 50 % 40 30 20 10 0

RESINA 2001-2012 Summary  The RESINA study provides a diverse and representative study cohort  TDR has to be expected in around 10% of chronically HIV-1 infected Patients  TDR is not decreasing in this cohort despite decreasing resistance in therapy-experienced patients;  TDR even tends to increase overall and in the NNRTI-group

RESINA-Study Centers Praxis Arbter, Krefeld Praxis Mauruschat, Wuppertal Praxis Baumann, Neuss Praxis Mauss, Schmutz, Hegener, Düsseldorf Praxis Becker-Boost, Duisburg Praxis Miasnikov, Düsseldorf Praxis Busch, Christenen, Münster Krankenhaus der Augustinerinnen, M. Oette, Köln Praxis Carls, Huber, Düsseldorf Klinikum Osnabrück, A. Mutz Praxis Dresch, Köln Uniklinik Düsseldorf, B. Jensen, T. Feldt, D. Häussinger Uniklinik Essen, S. Esser Praxis Reith, Düsseldorf Uniklinik Köln, G. Fätkenheuer Klinik Kemperhof, A. Rieke, Koblenz Praxis Ferdinand, Köln Uniklinik Bonn, J. Rockstroh Praxis Gantke, Düsseldorf Praxis Schäfer, Bielefeld Praxis Gippert, Hartmann, Quaing, Münster Praxis Schoelzel, Troisdorf Praxis Grüneberg, Münster Praxis Scholten, Köln Praxis Radecki, Köln Krankenhaus Hagen, T. Scholten, Hagen Klinikum Dortmund, M. Hower, Dortmund Praxis Schons, Düsseldorf Praxis Isernhagen, Römer, Qurishi, Köln Praxis Schuster, Wuppertal Praxis Knechten, Habets, Aachen Praxis Stechel, Juretzko, Köln Praxis Köthemann, Neuwirth, Köln Praxis Strehlow, Petry, Düsseldorf Praxis Kwirant, Duisburg Praxis Wiesel, Theisen, Voigt, Köln

Dieter Häussinger, Mark Oette, Stefan Reuter, Ulrike Haars, Falk Hüttig, Abdurrahman Sagir, Carola Blondin Department for Gastroenterology, Hepatology and Infectious Diseases University Hospital of Düsseldorf, Germany Rolf Kaiser, Claudia Müller, Herbert Pfister, Eugen Schülter, Melanie Balduin, Nadine Lübke, Finja Schweitzer, Jens Verheyen, Veronica di Cristanziano, Elena Knops, Angelika Hergesell Institute for Virology, University of Köln, Germany Thomas Lengauer and team, Niko Beerenwinkel Max Planck Institute for Bioinformatics, Saarbrücken